ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1710

Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level

Andre Lucas Ribeiro1, Sibel Aydin2, Gurjit Kaeley3, Fahmeen J. Afgani4, Catherine Bakewell5, Marcos Rosemffet6, Minna Kohler7, Amir Haddad8, Maria S. Stoenoiu9, Ari Polachek10, josefina marin11, Arnon Katz12, Sahil Koppikar13 and Lihi Eder14, 1Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, 2Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3UF COM-J, Ponte Vedra Beach, FL, 4Women's College Hospital, Toronto, Canada, 5Intermountain Healthcare, Salt Lake City, UT, 6Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 7Massachusetts General Hospital, Harvard Medical School, Boston, MA, 8Carmel Medical Centre, Haifa, Israel, 9Cliniques Universitaires Saint-Luc, Brussels, Belgium, 10Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, 11Hospital Universitario Rey Juan Carlos, Madrid, Spain, 12GRAPPA, Seattle, 13Women's College Hospital & University of Toronto, Markham, ON, Canada, 14University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2025

Keywords: Cohort Study, Diagnostic criteria, Imaging, Psoriatic arthritis, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

Session Type: Abstract Session

Session Time: 3:00PM-3:15PM

Background/Purpose: Enthesitis affects 30–40% of PsA patients but remains difficult to diagnose due to overlap with non-specific entheseal pain. While OMERACT has standardized ultrasound (US) elementary lesions, no validated definition of inflammatory enthesitis (IE) exists at the single-enthesis level. This limits diagnostic specificity and contributes to misclassification and overtreatment. We aimed to develop an expert- and data-driven definition of sonographic IE at the single-enthesis level in PsA, with the goal of improving diagnostic accuracy and patient selection for clinical research.

Methods: Ten expert sonographers from the DUET (Diagnostic Ultrasound Enthesitis Tool)1 study independently reviewed 90 US video scans of PsA patients at six entheseal sites. Each scan was score from –10 (“Definite not IE”) to +10 (“Definite IE”), and those with ≥70% agreement and scores of +7 were labeled “Definite IE.” Experts annotated key sonographic features influencing their assessments. Quantitative analysis included group comparison of elementary lesion distribution using the DUET consensus scoring for descriptive statistics and chi-square tests. Thematic analysis was performed on free-text annotations. This data was used to inform a proposed definition of IE, which was subsequently approved through a Delphi vote.

Results: Of 90 scans, 29 (32.2%) were “Definite IE”, 21 (23.3%) “Definite not IE”, and 40 (44.5%) “Uncertain”. Most “Definite IE” had ≥4 elementary lesions, while “Uncertain” scans commonly had 2 to 4 lesions (Figure 1A). The absence of elementary lesions or presence of isolated findings characterized the “Definite not IE” group.Power Doppler (PD) grade ≥ 2 near the bone cortex was present in 97% of the “Definite IE” group and in 55% of “Uncertain” scans (Figure 1B, Figure 2F). Importantly, grades 2-3 PD were almost exclusively found in these two groups, with grade 3 almost only found in the “Definite IE” group. Thematic analysis revealed that lesion combinations, cortical location of PD, and contextual interpretation were critical for classification. Isolated findings (e.g., small enthesophytes) lacked diagnostic value unless part of a broader inflammatory pattern. Structural lesions (e.g., cortical irregularities, erosions) were interpreted as signs of prior inflammatory process.Based on these findings the proposed definition for IE is ““The presence of a power Doppler signal grade ≥2 near the bone cortex, in the presence of hypoechogenicity and/or thickening of the entheseal structure, and within the appropriate clinical context*.” This excludes cases where findings are better explained by mechanical stress or trauma.” (Table 1). This definition achieved consensus in the Delphi exercise (10 out of 10 voted to approve).

Conclusion: The new proposed definition for sonographic IE in the context of PsA should facilitate the development of standardized diagnostic criteria for IE in PsA, and improve patient enrollment specificity in clinical research.Reference: Eder L, Aydin S, Kaeley G, et al. Arthritis Rheumatol. 2020;72(Suppl 10). Abstract.

Supporting image 1Table 1. New definition of inflammatory enthesitis at the single-enthesis level.

Supporting image 2Figure 1A . Number of elementary lesions identified in each category; 1B. Distribution of sonographic elementary lesions by category.

Supporting image 3Figure 2. The prevalence of elementary lesions by enthesitis definition category. 1A. Hypoechogenicity (score 0-1); 1B. Enthesophyte (score 0-3); 1C.

Thickening (score 0-1); 1D Calcification (Score 0-3); 1E. Erosion (score 0-1); 1F. Power Doppler (score 0-3). Chi-square test was performed to compare

the “definite enthesitis” and “uncertain” groups, with p-value < 0.05 marked with an asterisk (*) and a p-value < 0.01 marked with two asterisks.


Disclosures: A. Lucas Ribeiro: AbbVie/Abbott, 2, 6, Eli Lilly, 6, Janssen, 2, 6, Novartis, 6, UCB, 5, 6; S. Aydin: AbbVie/Abbott, 5, 6, Eli Lilly, 5, 6, Janssen, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, UCB, 5, 6; G. Kaeley: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, Janssen, 5, Novartis, 5; F. Afgani: None; C. Bakewell: AbbVie/Abbott, 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Novartis, 2, Pfizer, 2, 6, UCB, 2, 6; M. Rosemffet: None; M. Kohler: Janssen, 5, 12, medical advisory board, Novartis, 12, medical advisory board, Setpoint Medical, 5, Springer Publications, 9; A. Haddad: AbbVie/Abbott, 6, AstraZeneca, 6, Janssen, 6, Novartis, 6; M. Stoenoiu: AbbVie/Abbott, 5, 6, Janssen, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 5, 6, UCB, 5, 6; A. Polachek: None; j. marin: None; A. Katz: None; S. Koppikar: AbbVie/Abbott, 1, 2, 5, 6, Novartis, 2, 6, Pfizer, 12, Unrestricted educational grant for Northern Ontario Clinic, UCB, 2, 6; L. Eder: AbbVie, 1, 2, 5, 6, BMS, 1, 2, Eli Lilly, 1, 2, 5, 6, Fresenius Kabi, 1, 5, J&J, 1, 2, 5, Janssen, 1, 5, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, UCB, 1, 2, 5.

To cite this abstract in AMA style:

Lucas Ribeiro A, Aydin S, Kaeley G, Afgani F, Bakewell C, Rosemffet M, Kohler M, Haddad A, Stoenoiu M, Polachek A, marin j, Katz A, Koppikar S, Eder L. Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/defining-sonographic-enthesitis-in-psoriatic-arthritis-developing-a-data-and-expert-driven-definition-for-inflammatory-enthesitis-at-the-single-enthesis-level/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defining-sonographic-enthesitis-in-psoriatic-arthritis-developing-a-data-and-expert-driven-definition-for-inflammatory-enthesitis-at-the-single-enthesis-level/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology